Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON NASDAQ:OCS NASDAQ:QURE NASDAQ:VTYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.53+1.2%$2.23$1.60▼$2.77$957.60M1.134.02 million shs3.95 million shsOCSOculis$16.36+1.3%$17.94$11.56▼$23.08$704.28M0.2610,096 shs11,536 shsQUREuniQure$17.38+2.2%$14.83$4.45▼$19.18$895.98M0.14779,324 shs1.48 million shsVTYXVentyx Biosciences$2.58+4.9%$2.65$0.78▼$3.39$171.14M0.95605,048 shs373,323 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+1.20%-1.17%+25.25%+32.46%+12.95%OCSOculis+1.30%-5.60%-8.81%-16.36%+35.66%QUREuniQure+2.18%+10.35%+26.22%+4.64%+212.03%VTYXVentyx Biosciences+4.88%+2.79%-5.15%+14.67%+18.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group1.6618 of 5 stars0.03.00.00.02.50.02.5OCSOculis2.5151 of 5 stars3.53.00.00.03.20.00.6QUREuniQure1.9068 of 5 stars3.51.00.00.00.62.50.6VTYXVentyx Biosciences2.755 of 5 stars3.33.00.00.02.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/AOCSOculis 3.00Buy$35.75118.52% UpsideQUREuniQure 3.00Buy$37.45115.50% UpsideVTYXVentyx Biosciences 2.50Moderate Buy$7.50190.70% UpsideCurrent Analyst Ratings BreakdownLatest VTYX, CRON, QURE, and OCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.008/27/2025OCSOculisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.008/22/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $33.008/14/2025QUREuniQureMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$30.007/30/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$47.007/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$130.28M7.44N/AN/A$2.95 per share0.86OCSOculis$780K915.74N/AN/A$3.97 per share4.12QUREuniQure$27.12M35.16N/AN/A($0.07) per share-248.29VTYXVentyx BiosciencesN/AN/AN/AN/A$2.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.0550.6084.33N/A14.19%-3.78%-3.62%11/11/2025 (Estimated)OCSOculis-$97.43M-$2.67N/AN/AN/A-13,958.12%-90.31%-67.85%11/6/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)VTYXVentyx Biosciences-$135.12M-$1.68N/AN/AN/AN/A-48.89%-44.87%11/6/2025 (Estimated)Latest VTYX, CRON, QURE, and OCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025OCSOculis-$0.53-$0.59-$0.06-$0.59$0.14 million$0.25 million8/7/2025Q2 2025CRONCronos Group-$0.02-$0.10-$0.08-$0.10$45.73 million$33.46 million8/7/2025Q2 2025VTYXVentyx Biosciences-$0.45-$0.38+$0.07-$0.38N/AN/A7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.6523.53OCSOculis0.014.554.55QUREuniQure1.539.989.98VTYXVentyx BiosciencesN/A19.1219.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%OCSOculis22.30%QUREuniQure78.83%VTYXVentyx Biosciences97.88%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%OCSOculisN/AQUREuniQure4.79%VTYXVentyx Biosciences18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450383.04 million356.61 millionOptionableOCSOculis243.66 millionN/ANot OptionableQUREuniQure50054.87 million52.24 millionOptionableVTYXVentyx Biosciences3071.31 million58.35 millionOptionableVTYX, CRON, QURE, and OCS HeadlinesRecent News About These CompaniesVentyx Biosciences to Participate in Three Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comPiper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)August 23, 2025 | theglobeandmail.comH.C. Wainwright Keeps Their Hold Rating on Ventyx Biosciences (VTYX)August 23, 2025 | theglobeandmail.comVentyx Biosciences Reports Decreased Losses in 2025August 15, 2025 | msn.com3 Best Stocks to Buy Now, 8/11/2025, According to Top AnalystsAugust 11, 2025 | msn.comVentyx Biosciences (NASDAQ:VTYX) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPSAugust 10, 2025 | marketbeat.comWall Street Zen Upgrades Ventyx Biosciences (NASDAQ:VTYX) to "Hold"August 10, 2025 | marketbeat.comVentyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate ProgressAugust 9, 2025 | finance.yahoo.comVentyx (VTYX) Q2 Net Loss Drops 16%August 9, 2025 | theglobeandmail.comVentyx Biosciences (VTYX) Projected to Post Earnings on ThursdayAugust 7, 2025 | marketbeat.comIs Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?July 22, 2025 | uk.finance.yahoo.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - NasdaqJuly 11, 2025 | nasdaq.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?July 10, 2025 | zacks.comAnalysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)June 24, 2025 | theglobeandmail.comVTYX - Ventyx Biosciences Inc News - MorningstarJune 24, 2025 | morningstar.comMVTYX - Ventyx Biosciences Inc Financials - MorningstarJune 24, 2025 | morningstar.comMVentyx Biosciences Insiders Placed Bullish Bets Worth US$1.26mJune 17, 2025 | finance.yahoo.comVentyx Biosciences' Study of VTX3232 Met Safety, Tolerability ObjectivesJune 17, 2025 | marketwatch.comVentyx says Parkinson’s disease drug hit main goal in small mid-stage trialJune 17, 2025 | msn.comVentyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial ResultsJune 17, 2025 | msn.comVentyx Biosciences stock trades flat despite positive parkinson’s drug trial dataJune 17, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Deeply Undervalued, Micron Technologies Stock Isn’t Pricing in AIBy Thomas Hughes | August 14, 2025Micron Stock Still Cheap Despite 25% Rally, Analysts SayBy Gabriel Osorio-Mazilli | August 19, 2025VTYX, CRON, QURE, and OCS Company DescriptionsCronos Group NASDAQ:CRON$2.53 +0.03 (+1.20%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.52 -0.01 (-0.59%) As of 09/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Oculis NASDAQ:OCS$16.36 +0.21 (+1.30%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$16.56 +0.20 (+1.25%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.uniQure NASDAQ:QURE$17.38 +0.37 (+2.18%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$17.48 +0.11 (+0.60%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Ventyx Biosciences NASDAQ:VTYX$2.58 +0.12 (+4.88%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.58 +0.00 (+0.04%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
